Phillips, T. J. (2018). Phase 1 study of the PI3K{delta} inhibitor INCB040093 {+/-} JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationPhillips, T. J. Phase 1 Study of the PI3K{delta} Inhibitor INCB040093 {+/-} JAK1 Inhibitor Itacitinib in Relapsed/refractory B-cell Lymphoma. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationPhillips, T. J. Phase 1 Study of the PI3K{delta} Inhibitor INCB040093 {+/-} JAK1 Inhibitor Itacitinib in Relapsed/refractory B-cell Lymphoma. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.